CoLucid Pharmaceuticals was founded with a primary goal of developing lasmiditan for the acute treatment of migraine. The Company has three clinical trials underway—SAMURAI, SPARTAN, and GLADIATOR—which will result in more than 15,000 patient exposures with lasmiditan.
Lasmiditan is developed in two formulations: an oral medication for the acute treatment of migraine in adults, and also as intravenous formulation for administration by health care professionals.
In January 2017 – Eli Lilly and Company (NYSE:LLY) and CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential nearterm launch to its late-stage pipeline. CoLucid Pharmaceuticals is a public biopharmaceutical company developing an oral 5-HT1F agonist (lasmiditan) for the acute treatment of migraine. CoLucid has completed the first of two pivotal Phase 3 trials. A data read-out for the second Phase 3 trial, SPARTAN, is expected in the second half of 2017. If this trial is positive, submission of lasmiditan for U.S. regulatory approval could occur in 2018.